Figure 3. Multivariable Cox regression analysis of BMI and other clinical variables associated with response to ICI in EC patients.

Forest plots of adjusted HRs and 95% CIs for patients with normal BMI (BMI 18.5 – 24.9 kg/m2) (reference group) compared to overweight (BMI 25 – 29.9 kg/m2) and obese (BMI > 30 kg/m2) for (A) PFS and (B) (OS) (n=524) Analysis was adjusted for age, self-reported race, histology, checkpoint inhibitor treatment, combination therapies, baseline performance status, stage at diagnosis, prior lines of therapy, and previous pelvic radiotherapy. BMI, body mass index; OS, overall survival; PFS, progression free survival; EC, endometrial cancer; ICI, immune checkpoint inhibitor; Endo-LG, endometrial low grade; Endo-HG, endometrial high grade; Un-/dediff, Un-/dedifferentiated; Len/pem, Lenvatinib/pembrolizumab; Treme/durva, Tremelimumab/durvalumab; HR, Hazard ratio; CI, confidence interval.